Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04335292
Title Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge (OCELOT)
Acronym OCELOT
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mark Vincent
Age Groups: senior | adult
Covered Countries CAN

No variant requirements are available.